Ortho-k ready for success, but cost too high, says GlobalData

Article

Orthokeratology has re-emerged as a treatment for myopia, however, its high price tag may hinder its adoption in the corrective vision market.

 

London-Orthokeratology has re-emerged as a treatment for myopia and hyperopia, according to Joseph Gregory, an analyst with research and consulting firm GlobalData. Gregory added that, while the technology provides an intermediate solution between existing interventions, its high price tag may hinder its adoption in the corrective vision market.

Developed in the 1960s, orthokeratology uses rigid contact lenses that are worn at night to reshape the cornea and temporarily reduce a person’s refractive error. These contact lenses cost approximately $700, a significantly higher price than refractive surgery or soft contact lenses.

“While orthokeratology provides an intermediate solution between invasive and non-invasive interventions, the price of the lenses needs to be substantially lower than it is currently, especially with the corrective vision market being sensitive to economic conditions and consumer confidence,” Gregory said.

"LASIK surgery is a prime example of this. Prior to the most recent recession, there were U.S. procedure volumes of 1.4 million in 2007. Three years later, that figure decreased to 800,000 and it has not recovered since,” he added.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.